НовостиBenzingaSepterna Announces Selection Of SEP-204 As Potential Development Candidate For Treatment Of Graves’ Disease And TED; Reports Initial Preclinical Data Ahead Of Poster Presentation At 2026 ATA Annual Meeting Septerna Announces Selection Of SEP-204 As Potential Development Candidate For Treatment Of Graves’ Disease And TED; Reports Initial Preclinical Data Ahead Of Poster Presentation At 2026 ATA Annual Meeting Benzinga 2026.11.04 13:04 (GMT+0) Открыть на Benzinga Другие новости